As previously reported, BofA downgraded Charles River to Neutral from Buy with a price target of $215, down from $250, citing biopharma concerns. In a broader report on Life Sciences and Diagnostic Tools, the firm reviewed recent end-market datapoints and management commentary and points out that while there has been some stabilization and/or improvement in some areas, several major pockets of uncertainty and softness remain and are likely to persist into Q1 and the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River downgraded to Neutral from Buy at BofA
- Charles River downgraded to Sell from Neutral at Citi
- Charles River price target lowered to $190 from $191 at Baird
- Charles River announces collaboration with DanubeNeuro acceleration program
- Charles River, Insightec team on therapy in neuroscience with FUS